| HOME >> MEDICINE >> TECHNOLOGY |
SHANGHAI, Aug. 3, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that the independent committee of the Company's board of directors (the "Independent Committee"), consisting of three of the Company's independent directors, Mr. Yuk Lam Lo, Mr. Julian Ralph Worley and Mr. Benson Tsang, has retained J.P. Morgan Securities (Asia Pacific) Limited ("J.P. Morgan") as its financial advisor.
As the Independent Committee's financial advisor, J.P. Morgan will, together with O'Melveny & Myers LLP ("O'Melveny"), the Independent Committee's legal advisor, assist the Independent Committee in reviewing and evaluating the July 6, 2012 non-binding proposal from the Company's Chairman and Chief Executive Officer, Mr. Michael Xin Hui, and entities affiliated with him (collectively, the "Founder") and TPG Star Charisma Limited and its affiliates (collectively, "TPG") to acquire all of the outstanding shares of ShangPharma not currently owned by the Founder or TPG (the "Proposal"). J.P. Morgan and O'Melveny will also assist the Independent Committee in reviewing and evaluating any additional proposals that may be made by the Founder, TPG or other parties, if any.
The Independent Committee is continuing its evaluation of the Proposal. There can be no assurance that any definitive offer will be made, that any definitive agreement will be executed, that the Independent Committee will recommend the Proposal or that this or any other transaction will be consummated.
About ShangPharma Corporation
ShangPharma Corporation (NYSE: SHP) is a leading China-based contract research organization providing high-quality and cost-effective servic
'/>"/>
| SOURCE ShangPharma Corporation Copyright©2012 PR Newswire. All rights reserved |